Legal saga involving the drug Entresto (Novartis) in the United States

Of the 25 complaints Novartis has filed against 18 generic companies for alleged infringement of nine of its Entresto patents – bearing in mind that a complaint can involve several companies and patents – only two verdicts have been delivered so far (one in favour, the other against Novartis, which has lodged an appeal). That represents almost five years of sales at a high price, without competition.

